PROCESS FOR PRODUCING MEDICAL-GRADE LEAD-212

Abstract

The invention relates to a process for producing medical-grade lead-212, comprising the steps of: a) production of lead-212 by radioactive decay of radium-224 in at least one first chromatography column containing a first stationary phase on which radium-224 is fixed; b) elution of the lead-212 thus produced from the first stationary phase; c) loading of the eluate thus obtained into a second chromatography column containing a second stationary phase to fix the lead-212 on the second stationary phase; d) washing of the second stationary phase; d) elution of the lead-212 from the second stationary phase; and characterized in that: - step b) comprises circulating in said at least one first chromatography column an ​​aqueous solution A1 comprising from 0.8 mol / L to 1.6 mol / L of a chloride, optionally with at most 200 mmol / L of HCl;and- step d) includes circulating an aqueous solution A2 comprising 0.01 mol / L to 1 mol / L of chloride through the second chromatography column. Applications: manufacture of lead-212 based radiopharmaceuticals, useful in nuclear medicine.

Description

Title of the invention: METHOD FOR PRODUCING MEDICAL GRADE LEAD-212 technical field

[0001] The invention relates to the field of the production of radioactive isotopes, also called radioisotopes.

[0002] More specifically, it relates to a process which makes it possible to produce lead-212 exhibiting a very high degree of radiological purity, which makes it fully suitable for medical use.

[0003] This process is therefore likely to find applications in the manufacture of lead-212 based radiopharmaceuticals, useful in nuclear medicine and, in particular, in targeted alpha radiotherapy for the treatment of cancers. Prior art

[0004] Lead-212 is a rare radioactive isotope of lead, which has been the subject of promising research for several years, particularly for the treatment by targeted alpha radiotherapy, also called targeted alpha therapy, of cancers and, in particular, cancers of the pancreas, ovaries, colon, breast and prostate.

[0005] Lead-212 is also among the radioisotopes which have been shown to be of interest in medical imaging, in particular for performing examinations by single-photon emission computed tomography coupled with a scanner.

[0006] In both cases, the use of lead-212 implies that it is injected into the patient in the form of a radiopharmaceutical, that is to say a product in which it is linked, typically via a chelating agent, to a molecule capable of very specifically targeting the cells that one wishes to destroy (if it is targeted alpha therapy) or observe (if it is medical imaging), such as a peptide.

[0007] To achieve this, lead-212 must meet extremely strict quality requirements and, in particular, radiological purity, which should ideally be at least equal to 99.95%.

[0008] In this regard, it is specified that the radiological purity of a radioisotope such as lead-212 is understood to mean the purity that this radioisotope exhibits with respect to the radioisotopes from which it originates by radioactive decay (i.e. its ascendants) as well as with respect to other radioisotopes that are not part of its radioactive decay chain, and not the purity that this radioisotope exhibits with respect to the radioisotopes to which it gives rise by its own radioactive decay (i.e. its descendants).

[0009] As illustrated in Figure 1 attached in the appendix, which represents the radioactive decay chain of thorium-232, lead-212 belongs to the thorium-232 radioactive decay series, of which it is a decay product. It is also a decay product of thorium-228 and radium-224, which are located in this chain between thorium-232 and lead-212.

[0010] To produce medical-grade lead-212, i.e., meeting the aforementioned requirements for radiological purity, processes have been proposed in international PCT applications WO-A-2013 / 174949 and WO-A-2017 / 093069, hereinafter referred to as [1] and [2], which schematically comprise: - the production of lead-212 by radioactive decay of radium-224 in a generator which includes a stationary phase on which radium-224 is fixed and which will be more simply called a Ra-224 / Pb-212 generator in what follows; - the elution of the lead-212 thus produced from the stationary phase of the Ra-224 / Pb-212 generator, then - the purification of the lead-212 thus eluted by liquid chromatography.

[0011] These references also describe devices specially designed for automated implementation, in a closed system, of these processes.

[0012] References [1] and [2] both describe eluting lead-212 from the stationary phase of the Ra-224 / Pb-212 generator with an aqueous solution containing 1.5 mol / L to 2.5 mol / L of a strong acid such as hydrochloric acid or nitric acid, the acid used in the examples in these references being hydrochloric acid at a concentration of 2 mol / L. This elution leads to the production of a strongly acidic eluate which is then loaded into the chromatography column used for the purification of lead-212.

[0013] However, the use of hydrochloric acid at the concentrations recommended in references [1] and [2] and, in particular, of 2M hydrochloric acid poses corrosion problems for equipment that may be used for the production of lead-212, such as automated elution devices, some components of which (valve bodies, screws or bearings for example) are sensitive to acids, as well as for nearby steel surfaces such as those of glove boxes or armored chains, resulting in a high maintenance rate.

[0014] Furthermore, in reference [2], it is envisaged that the process may include, upstream of the production of lead-212 in the Ra-224 / Pb-212 generator, a step aimed at producing radium-224 itself by radioactive decay of thorium-228 in a generator comprising a stationary phase to which this thorium is fixed and which will be referred to more simply as the Th-228 / Ra-224 generator in what follows. It is specified that, in this case, the elution of radium-224 from this stationary phase for the purpose of its recovery is carried out with an acidic aqueous solution such as a hydrochloric acid solution. The hydrochloric acid concentration of this elution solution is not specified, but it can be deduced from reference [2] that this concentration is between 1 mol / L and 3 mol / L, since the eluate containing radium-224, which is subsequently used to fix this radium to the stationary phase of the Ra-224 / Pb-212 generator, has a hydrochloric acid concentration between 1 mol / L and 3 mol / L, and preferably 2 mol / L. The use of such an elution solution therefore poses the same corrosion problems as those mentioned previously. Furthermore, the retention curve of thorium-228 by the DGA (Triskem International) resin, whose use is recommended in reference [2] as the stationary phase of the Th-228 / Ra-224 generator, shows a very steep slope in 3M IM hydrochloric acid.Consequently, even the slightest approximation of the molarity of this acid exposes the generator to a high risk of thorium-228 leakage and / or a reduction in its lifespan.

[0015] In view of the foregoing, the inventors have set themselves the objective of providing a process for the production of lead-212 which, while exhibiting the same performance as the processes described in references [1] and [2], in particular in terms of yield and quality of the lead-212 produced, is free from the disadvantages mentioned above.

[0016] They also set themselves the objective of improving the elution performance of lead-212 during its purification by liquid chromatography and, more specifically, of reducing the volume of elution solution required to elut all of the available activity of lead-212.

[0017] They have further set themselves the objective that this process can be implemented in an automated manner, for example by means of one of the devices described in references [1] and [2]. Description of the invention

[0018] These objectives are met by the invention, which proposes a process for producing medical-grade lead-212, comprising at least the steps of: a) production of lead-212 in at least one Ra-224 / Pb-212 generator, i.e. by radioactive decay of radium-224 present in at least one first chromatography column containing a first stationary phase on which radium-224 is fixed; b) elution of the lead-212 thus produced from the first stationary phase to obtain an eluate comprising unpurified lead-212; c) loading the eluate thus obtained into a second chromatography column containing a second stationary phase to fix the lead-212 present in the eluate onto the second stationary phase; d) washing of the second stationary phase to remove radioactive impurities that may have been retained by the second stationary phase without removing lead-212; and e) elution of lead-212 from the second stationary phase, whereby medical-grade lead-212 is obtained in aqueous solution; and which is characterized in that: - step b) includes circulating in said at least one first chromatography column an ​​aqueous solution A1 comprising from 0.8 mol / L to 1.6 mol / L of a chloride, alone or in mixture with at most 200 mmol / L of hydrochloric acid; and - step d) includes circulating in the second chromatography column an ​​aqueous solution A2 comprising from 0.01 mol / L to 1 mol / L of the chloride.

[0019] Thus, according to the invention, the aqueous solution, which is used in step b) to elute lead-212 from the stationary phase of the Ra-224 / Pb-212 generator(s), is a solution that includes a chloride and in which hydrochloric acid may be present, but at a concentration infinitely lower than that recommended in references [1] and [2]. Consequently, the same applies to the eluate that is loaded into the second chromatography column in step c).

[0020] Furthermore, the washing(s) of the stationary phase on which lead-212 is fixed -or step d) - is (are) carried out with an aqueous solution comprising a chloride and not with an aqueous solution of hydrochloric acid as described in the examples in references [1] and [2].

[0021] The risks of corrosion of equipment and surrounding surfaces are thus eliminated or, at the very least, drastically reduced, resulting in a reduction of the maintenance rate and, consequently, of the production costs of lead-212, without affecting the level of radiological purity obtained.

[0022] In accordance with the invention, the first and second stationary phases are preferably of the same type as those used in references [1] and [2] to respectively produce lead-212 in the Ra-224 / Pb-212 generator and then purify this lead, that is to say: - the first stationary phase is preferably a cation exchange resin that retains radium, regardless of its isotope, but does not retain lead in the presence of chloride ions, regardless of their isotope, such as a resin made of particles of an organic polymer, such as poly(styrene-co-divinylbenzene), onto which sulfonic groups, SO3H, are grafted, of the type available from Bio-Rad under the trade name AG™ MP-50, while - the second stationary phase is preferably an extraction resin made of particles of an inert support impregnated with a crown ether, such as dicyclohexano-18-crown-6 or dibenzo-18-crown-6, whose groups cyclohexyls or benzyls are substituted by one or more alkyl groups in C12 to C11, straight or branched chain; thus, the second stationary phase can in particular be a resin whose inert support is impregnated with 4,4'(5')-di-tert-butylcyclohexano-18-crown-6 in isodecanol solution, such as that available from Triskem International under the trade name PB Resin.

[0023] The chloride present in aqueous Al and A2 solutions can be chosen from among many salts comprising at least one chloride anion. In particular, it can be a chloride of a metal and, especially, a chloride of an alkali metal, such as sodium or potassium chloride, or of an alkaline earth metal, such as calcium or magnesium chloride, or even ammonium chloride. Among these salts, preference is given to magnesium chloride.

[0024] According to the invention, the aqueous solution Al comprises, preferably, from 0.8 mol / L to 1.2 mol / L and, even better, 1.0 mol / L of magnesium chloride, alone or in a mixture with at most 50 mmol / L of hydrochloric acid, this acid being, if present, preferably at a concentration of 1 mmol / L.

[0025] The aqueous solution A2 preferably comprises from 0.1 mol / L to 1 mol / L and, even better, 1 mol / L of magnesium chloride.

[0026] Knowing that, like any chromatography column, the second column has two opposite ends, respectively called the head and tail of the column, step d) includes the circulation of a first volume of aqueous solution A2 from the head of the column to the tail of the column, and then the circulation of a second volume of aqueous solution A2, identical or different from the first volume, from the tail of the column to the head of the column.

[0027] Step e) includes, in the second chromatography column, the circulation of an aqueous solution A3, which advantageously has a pH between 5 and 9 and preferably includes one or more complexing or chelating agents - the two terms being considered here as synonyms - and / or antioxidant agents.

[0028] The complexing or chelating agent(s) may be chosen in particular from: - ammonium acetate which is preferably used at a concentration ranging from 0.15 mol / L to 1 mol / L; - citric acid and its salts such as the citrates of an alkali metal (like monosodium citrate, disodium citrate or trisodium citrate), the citrates of an alkaline earth metal (like monocalcium citrate, dicalcium citrate or tricalcium citrate) or even ammonium citrates such as monobasic ammonium citrate, dibasic ammonium citrate or tribasic ammonium citrate, which is preferably used at a concentration ranging from 10 mmol / L to 200 mmol / L, with preference given to citric acid; and - chelators which are typically used in the preparation of products intended for nuclear medicine and, in particular, derivatives of cyclene, i.e. of 1,4,7,10-tetraazacyclododecane, such as DOTA (or 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid) or DOTAM (or 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic amide), which then allows precious time to be saved in the manufacture of lead-212 based radiopharmaceuticals given that the half-life of the latter is only 10.6 hours; if such chelators are used, then they are preferentially used at a rate of 0.2 pmol / L to 200 pmol / L.

[0029] The antioxidant agent(s) may, in particular, be chosen from ascorbic acid and citric acid, which are preferably used at a concentration ranging from 10 mmol / to 200 mmol / L.

[0030] Advantageously, the aqueous solution A3 comprises ammonium acetate and citric acid (which acts as both a complexing and antioxidant agent) and / or DOTAM. Thus, for example, the aqueous solution A3 may comprise 0.4 mol / L of ammonium acetate and 75 mmol / L of citric acid or 0.4 mol / L of ammonium acetate, 75 mmol / L of citric acid and 2 pmol / L of DOTAM.

[0031] In any case, the aqueous solution A3 is preferably circulated in the second chromatography column from the column tail to the column head.

[0032] Advantageously, the process is implemented using m Ra-224 / Pb-212 generators, i.e. m first chromatography columns each containing a first stationary phase on which radium-224 is fixed, m being an integer at least equal to 2, typically between 2 and 4, and a single second chromatography column.

[0033] In this case, the first m chromatography columns can be arranged in parallel, in which case: - steps a) and b) in each of the first m chromatography columns, whereby m eluates comprising unpurified lead-212 are obtained, which are collected separately or together to form a mixture of the m eluates; - step c) by loading the eluates or the mixture of eluates thus obtained into the second chromatography column containing the second stationary phase; - step d) of washing the second stationary phase; and - step e) of elution of lead-212 from the second stationary phase.

[0034] Thus, by loading these eluates (separately or as a mixture) into the second chromatography column, it is possible to increase the amount of unpurified lead-212 that binds to the second stationary phase and, consequently, to concentrate the lead-212 in the aqueous solution resulting from the elution planned in step e).

[0035] Alternatively, the first m chromatography columns can be connected in series, in which case: - steps a) and b) in each of the first m chromatography columns, step b) being carried out by circulating the aqueous solution Al successively in the said first m chromatography columns, whereby an eluate comprising unpurified lead-212 is obtained at the exit of the first m of these columns; - step c) by loading the eluate thus obtained into the second chromatography column containing the second stationary phase; - step d) of washing the second stationary phase; and - step e) of elution of lead-212 from the second stationary phase.

[0036] Thus, with this variant, it proved possible to elute lead-212 from m Ra-224 / Pb-212 generators using a significantly smaller volume of aqueous solution Al than would be required to elute the same quantity of lead-212 from m Ra-224 / Pb-212 generators having the same lead-212 charge but which would not be connected in series, resulting in a saving of reagents, a concentration of unpurified lead-212 in the single eluate obtained from the m Ra-224 / Pb-212 generator and, consequently, better fixation of this lead on the stationary phase of the second chromatography column (since it is present in a smaller volume) and a concentration of lead-212 in the aqueous solution from the elution planned in step e).

[0037] Regardless of the variant, two or three first chromatography columns are preferably used, i.e. m = 2 or 3.

[0038] According to the invention, the method preferably also comprises, before step a), the steps of: (i) production of radium-224 in at least one Th-228 / Ra-224 generator, i.e., by radioactive decay of thorium-228 in at least one third chromatography column comprising a third stationary phase on which thorium-228 is fixed; and ii) elution of the radium-224 thus produced from the third stationary phase to obtain an eluate comprising radium-224, the elution comprising circulation in said at least a third chromatography column of an aqueous solution A0 comprising from 0.4 mol / L to 1 mol / L of nitric acid; then iii) loading the eluate thus obtained into said at least one first chromatography column to fix the radium-224 present in the eluate onto the first stationary phase.

[0039] According to the invention, the third stationary phase is preferably an extraction resin consisting of particles of an organic polymer, such as a polymethacrylate or a poly(styrene-co-divinylbenzene), impregnated with an actinide ligand such as a tetraalkylated diglycolamide (for example, A,A,A',A'-tetraoctyl-diglycolamide or TODGA), a dialkylphosphoric acid (for example, di(2-ethylhexyl)phosphoric acid or HDEHP) or a trialkylphosphine oxide (for example, trioctylphosphine oxide or TOPO).

[0040] Thus, the third stationary phase can in particular be a resin whose polymer is impregnated with TODGA, such as that available from the company Triskem International under the trade name DGA Normal Resin.

[0041] Preferably, the aqueous solution A0 comprises from 0.5 mol / L to 0.75 mol / L and, even better, 0.5 mol / L of nitric acid.

[0042] Advantageously, n Th-228 / Ra-224 generators are used, that is to say n third chromatography columns each containing a third stationary phase on which thorium-228 is fixed, n being an integer at least equal to 2, typically between 2 and 5.

[0043] In this case, the n third chromatography columns can be arranged in parallel, in which case: - steps i) and ii) in each of the n third chromatography columns, thereby obtaining n eluates comprising radium-224 which are collected separately or together to form a mixture of the n eluates; and - step iii) by loading the n eluates or the mixture of the n eluates thus obtained into said at least one first chromatography column.

[0044] This makes it possible to increase the amount of radium-224 which is fixed in step iii) on the stationary phase contained in said at least one first chromatography column and, as a result, to increase the amount of lead-212 produced by radioactive decay of radium-224 in step a).

[0045] Alternatively, the n third chromatography columns can be connected in series, in which case: - steps i) and ii) in each of the n third chromatography columns, step ii) being carried out by circulating the aqueous solution A0 successively through said n third chromatography columns, thereby obtaining, at the exit of the nth of these columns, an eluate comprising radium-224; and - step iii) by loading the eluate thus obtained into said at least one first chromatography column.

[0046] Here too, this variant makes it possible to elute radium-224 from n Th-228 / Ra-224 generators using a significantly smaller volume of aqueous solution A0 than that which would be required to elute the same quantity of radium-224 from n Th-228 / Ra-224 generators having the same radium-224 charge but not connected in series, resulting in reagent savings, a concentration of radium-224 in the single eluate obtained from the nth Th-228 / Ra-224 generator and, consequently, better fixation of this radium on the stationary phase of said at least first chromatography column or, in other words, of said at least one Ra-224 / Pb-212 generator.

[0047] Regardless of the variant, two or three third chromatography columns are preferably used, i.e. n = 2 or 3.

[0048] Other features and advantages of the process of the invention will become apparent from the reading of the following supplementary description which relates to methods of implementing this process.

[0049] It goes without saying that these modes of implementation are given only as examples and do not in any way constitute a limitation of the object of the invention. Brief description of the figures

[0050] [Fig. 1], already commented on, represents the radioactive decay chain of thorium-232.

[0051] [Fig.2] schematically represents a first method of implementing the process of the invention.

[0052] [Fig.3] schematically represents a second implementation method of the process of the invention.

[0053] Detailed description of particular implementation methods

[0054] Reference is made to [Fig.2] which schematically illustrates the different steps, noted 1 to 6, of a first mode of implementation of the process of the invention, in which a single Th-228 / Ra-224 generator and a single Ra-224 / Pb-212 generator are used.

[0055] In this embodiment, the starting point of the process is therefore represented by a Th-228 / Ra-224 generator, labeled 10 in [Fig.2]. This generator comprises a chromatography column whose stationary phase, labeled 20, consists of DGA Normal resin particles (Triskem International) and to which thorium-228 is fixed.

[0056] Since the thorium-228 present in generator 10 has been allowed to decay to produce radium-224, the process comprises the following steps: 1. the elution of the radium-224 thus produced from the stationary phase 20 by means of an aqueous solution A0 of nitric acid to obtain an eluate El comprising radium-224; 2. the preparation of a Ra-224 / Pb-212 generator, denoted 30, by loading the eluate El into a chromatography column, the stationary phase 40 of which consists of AG™ MP-50 resin particles (Bio-Rad), to fix the radium-224 present in this eluate onto the stationary phase 40; 3. radium-224 present in generator 30 having been allowed to decay to produce lead-212, the elution of this lead from the stationary phase 40 by means of an aqueous solution Al of a chloride, alone or in mixture with very weakly concentrated hydrochloric acid, to obtain an eluate E2 comprising lead-212; 4. the loading of the eluate E2 into a chromatography column, noted 50, whose stationary phase 60 consists of particles of PB Resin (Triskem International), to fix the lead-212 present in this eluate onto this stationary phase; 5. two successive washes of the stationary phase 60 to remove from the column 50, and in particular from the interstitial volume of this stationary phase, traces of radioisotopes other than lead-212 that may have been retained in this column in the previous step, each of these washes being carried out with an aqueous solution A2 of a chloride but in the opposite direction to each other; 6. the elution of lead-212 from the stationary phase 60 by means of an aqueous solution A3 having a pH ranging from 5 to 9 and comprising one or more complexing agents and / or antioxidant agents to obtain an eluate E3 comprising purified lead 212 and the collection of this eluate in a receptacle, noted 70, which may be of the type beaker, flask, or similar, as illustrated in [Fig.2], but which may also be a syringe connected to the tail of column 50.

[0057] All these steps, which are detailed below, are carried out at room temperature, i.e. at a temperature of 20 °C to 25 °C.

[0058] Moreover, all solutions used are preferably of Optima™ grade or prepared from Optima™ grade reagents or Trace Metals grade reagents.

[0059] Unless otherwise specified, aqueous solutions that are circulated in columns 10, 30 and 50 are circulated from the top of the column to the tail of the column.

[0060] * Step 1:

[0061] As previously indicated, this step consists of eluting, from the stationary phase 20 of the generator 10, the radium-224 which has been produced by radioactive decay of the thorium-228 fixed on this stationary phase.

[0062] This generator includes a chromatography column which has, for example, a bed volume, or BV for Bed Volume, ranging from 5 mL to 100 mL and which is filled with DGA Normal resin particles, for example at a level of 2 g to 40 g of particles depending on the BV of the column.

[0063] This type of resin retains thorium, whatever its isotope, but does not retain radium, whatever its isotope.

[0064] The elution of radium-224 is carried out by circulating in the generator 10 several BV of aqueous solution AO - which comprises from 0.5 mol / L to 0.75 mol / L and, preferably, 0.5 mol / L of nitric acid - at a flow rate which is, for example, 0.25 BV / min.

[0065] The EL eluate is thus obtained

[0066] * Step 2:

[0067] The generator 30 is prepared using a chromatography column of smaller dimensions than those of the chromatography column of the generator 10 and which has, for example, a BV ranging from 0.5 mL to 10 mL, and which is filled with AG™ MP-50 resin particles, for example at a level of 300 mg to 5 g of particles depending on the BV of this column, and circulating the eluate El in this column.

[0068] In chloride media, the AG™ MP-50 resin retains radium, regardless of the isotope, but does not retain lead, regardless of the isotope.

[0069] The loading of the eluate El into the generator 30 is carried out at a flow rate which is, for example, 4 BV / min.

[0070] * Step 3:

[0071] As previously indicated, this step consists, after a period of time during which the generator 30 has been allowed to produce lead-212 by radioactive decay of radium-224 present in this generator, of eluting the lead-212 thus produced from the stationary phase 40.

[0072] To do this, several BVs of aqueous solution Al are circulated in the generator 30, for example at a flow rate of 4 BV / min, this aqueous solution comprising from 0.8 mol / L to 1.6 mol / L of a chloride, advantageously magnesium chloride, and possibly hydrochloric acid, this acid, if present, having a concentration of at most 200 mmol / L, preferably at most 50 mmol / L and, even better, of 1 mmol / L.

[0073] E2 is thus obtained.

[0074] * Step 4:

[0075] Since the lead-212 present in the eluate E2 does not yet meet the radiological purity criterion required for medical use, steps 4, 5 and 6 aim to purify the lead-212 with respect to its precursors, and in particular with respect to radium-224, by means of a chromatography column filled with PB resin.

[0076] The chromatography column 50 used for this purpose, which is smaller in size than the chromatography column of the generator 30, has, for example, a BV ranging from 0.1 mL to 1 mL and is filled with 35 mg to 450 mg of PB Resin particles.

[0077] The loading of the eluate E2 into the column 50 is carried out by circulating this eluate in the column 50 at a flow rate which is, for example, 4 BV / min.

[0078] * Step 5:

[0079] The two successive washes planned in this step are carried out with the same aqueous solution A2 but in the opposite direction to each other.

[0080] This aqueous solution comprises from 25 mmol / L to 75 mmol / L of the same chloride as that present in the aqueous solution Al used in step 3 above, for example 50 mmol / L of magnesium chloride.

[0081] The first wash is carried out by circulating several BVs of aqueous solution A2 in the column 50, from the top of the column to the tail of the column, for example at a flow rate of 6 BV / min, while the second wash is carried out by circulating in this column, preferably, the same number of BVs of aqueous solution A2 and at the same flow rate but from the tail of the column to the top of the column.

[0082] * Step 6:

[0083] The elution of lead-212 from the stationary phase 60 is carried out by circulating in the column 50, from the tail of the column to the head of the column, several BVs of aqueous solution A3, which has a pH between 5 and 9 and includes one or more complexing agents and / or antioxidant agents.

[0084] The aqueous solution A3 is, for example, an aqueous solution which has a pH of 6.5 and comprises 0.4 mol / L of ammonium acetate and 75 mmol / L of citric acid.

[0085] It is put into circulation in column 50 at a flow rate, for example, of 6 BV / min.

[0086] The eluate E3 thus obtained at the top of the column is collected in container 70 and the lead-212 present in this eluate exhibits radiological purity with respect to its precursors, allowing its use for medical purposes.

[0087] As previously indicated, the process as just described can also be implemented using n Th-228 / Ra-224 generators, n being for example equal to 3, arranged in parallel or connected in series, as well as with m Ra-224 / Pb-212 generators, m being for example equal to 2, also arranged in parallel or connected in series.

[0088] Thus, for example, as illustrated in [Fig. 3], which illustrates an implementation of the process in which n Th-228 / Ra-224 generators connected in series and m Ra-224 / Pb-212 generators connected in series are used, this implementation differs from that shown in [Fig. 2] only in that: - thorium-228 having been allowed to decay in the n generators 10 to produce radium-224, step 1 is carried out by circulating the aqueous solution A0 of nitric acid successively through these n generators 10 or, in other words, by introducing this solution into the first of the n generators 10 and circulating it through the n -1 the following 10 generators, which leads to obtaining a single eluate El comprising radium-224 at the exit of the nth generator 10; - Step 2 is carried out by circulating the eluate thus obtained successively through the m generators 30 or, in other words, by introducing this eluate into the first of the m generators 30 and circulating it through the following m-1 generators 30; and - radium-224 having been allowed to decay in the m generators 30 to produce lead-212, step 3 is carried out by circulating the aqueous solution Al successively through these m generators 30 or, in other words, by introducing this solution into the first of the m generators 30 and circulating it through the following m-1 generators 30, which leads to obtaining a single eluate E2 comprising unpurified lead-212 at the exit of the same generator 30. References cited

[0089] [1] WO-A-2013 / 174949

[0090] [2] WO-A-2017 / 093069

Claims

Demands

1. A process for producing a medical-grade aqueous solution of lead-212, comprising at least the steps of: a) producing lead-212 by radioactive decay of radium-224 present in at least a first chromatography column (30) containing a first stationary phase (40) to which radium-224 is fixed; b) eluting the lead-212 thus produced from the first stationary phase to obtain an eluate comprising unpurified lead-212; c) loading the eluate thus obtained into a second chromatography column (50) containing a second stationary phase (60) to fix the lead-212 present in the eluate onto the second stationary phase; d) washing the second stationary phase to remove radioactive impurities that may have been retained by the second stationary phase without removing the lead-212;then e) elution of lead-212 from the second stationary phase, thereby obtaining medical-grade lead-212 in aqueous solution; and which is characterized in that: - step b) comprises circulating in said at least a first chromatography column (30) an aqueous solution A1 comprising from 0.8 mol / L to 1.6 mol / L of a chloride, alone or in mixture with at most 200 mmol / L of hydrochloric acid; and - step d) comprises circulating in the second chromatography column (50) an aqueous solution A2 comprising from 0.01 mol / L to 1 mol / L of the chloride.

2. A process according to claim 1, wherein the chloride present in aqueous Al and A2 solutions is an alkali metal chloride, an alkaline earth metal chloride, or ammonium chloride.

3. The method according to claim 2, wherein the chloride is magnesium chloride.

4. A method according to any one of claims 1 to 3, wherein the aqueous solution Al comprises from 0.8 mol / L to 1.2 mol / L and preferably 1.0 mol / L of magnesium chloride, alone or mixed with at most 50 mmol / L of hydrochloric acid.

5. A method according to any one of claims 1 to 4, wherein the aqueous solution A2 comprises from 0.1 mol / L to 1 mol / L and preferably 1 mol / L of magnesium chloride.

6. A method according to any one of claims 1 to 5, wherein the second chromatography column (50) has a column head and a column tail and step d) comprises circulating a first volume of aqueous solution A2 from the column head to the column tail, and then circulating a second volume of aqueous solution A2 from the column tail to the column head.

7. A method according to any one of claims 1 to 6, wherein step e) comprises circulating in the second chromatography column (50) an aqueous solution A3 of pH between 5 and 9 and comprising one or more complexing agents and / or antioxidant agents.

8. A process according to claim 7, wherein the aqueous solution A3 comprises ammonium acetate and citric acid and / or DOTAM.

9. A process according to claim 8, wherein the aqueous solution A3 comprises 0.4 mol / L of ammonium acetate and 75 mmol / L of citric acid.

10. A method according to any one of claims 7 to 9, wherein the second chromatography column (50) has a column head and a column tail and the aqueous solution A3 flows in the second chromatography column from the column tail to the column head.

11. A method according to any one of claims 1 to 10, wherein m first chromatography columns arranged in parallel are used, each containing a first stationary phase to which radium-224 is fixed, m being an integer at least equal to 2, typically between 2 and 4, and the following are carried out: - steps a) and b) in each of the first m chromatography columns, thereby obtaining m eluates comprising unpurified lead-212, which are collected separately or together to form a mixture of the m eluates; - step c) by loading the m eluates or the mixture of m eluates thus obtained into the second chromatography column containing the second stationary phase; - step d) of washing the second stationary phase; and - step e) of elution of lead-212 from the second stationary phase.

12. A method according to any one of claims 1 to 10, wherein m first chromatography columns connected in series are used, each containing a first stationary phase on which radium-224 is fixed, m being an integer at least equal to 2, typically between 2 and 4, and the following are carried out: - steps a) and b) in each of the first m chromatography columns, step b) being carried out by circulating the aqueous solution Al successively through the first m chromatography columns, thereby obtaining, at the exit of the first m chromatography columns, an eluate comprising unpurified lead-212; - step c) by loading the eluate thus obtained into the second chromatography column containing the second stationary phase; - step d) of washing the second stationary phase; and - step e) of eluting the lead-212 from the second stationary phase.

13. Method according to claim 11 or claim 12, wherein m is equal to 2 or 3.

14. A method according to any one of claims 1 to 13, further comprising, prior to step a), the steps of: i) producing radium-224 by radioactive decay of thorium-228 in at least one third chromatography column (10) comprising a third stationary phase (20) on which thorium-228 is fixed; and ii) eluting the radium-224 thus produced from the third stationary phase to obtain an eluate comprising radium-224, the elution comprising circulating in said at least one third chromatography column an ​​aqueous solution AO comprising from 0.4 mol / L to 1 mol / L of nitric acid; and then iii) loading the eluate thus obtained into said at least one first chromatography column (30) to fix the radium-224 present in the eluate onto the first stationary phase (40).

15. A process according to claim 14, wherein the aqueous solution A0 comprises 0.5 mol / L of nitric acid.

16. A method according to claim 14 or claim 15, wherein n third chromatography columns arranged in parallel are used, each containing a third stationary phase on which thorium-228 is fixed, n being an integer at least equal to 2, typically between 2 and 5, and the following are carried out: - steps i) and ii) in each of the n third chromatography columns, thereby obtaining n eluates comprising radium-224 which are collected separately or together to form a mixture of the n eluates; and - step iii) by loading the n eluates or the mixture of the n eluates thus obtained into said at least one first chromatography column.

17. A method according to claim 14 or claim 15, wherein n third chromatography columns connected in series are used, each containing a third stationary phase on which thorium-228 is fixed, n being an integer at least equal to 2, typically between 2 and 5, and the following are carried out: - steps i) and ii) in each of the n third chromatography columns, step ii) being carried out by circulating the aqueous solution AO successively through the n third chromatography columns, thereby obtaining, at the exit of the nth of the n third chromatography columns, an eluate comprising radium-224; and - step iii) by loading the eluate thus obtained into said at least one first chromatography column.

18. Method according to claim 16 or claim 17, wherein n is equal to 2 or 3.

Images